
Akanda, Tilray Brands, Canopy Growth, SNDL, and Quantum Biopharma are the five Cannabis stocks to watch today, according to MarketBeat’s stock screener tool. Cannabis stocks are shares of publicly traded companies whose primary business involves the cannabis plant or related products and services — for example cultivation, processing, retail, hemp/CBD products, biotech research, or ancillary services and equipment. They offer investors exposure to the legal cannabis market but tend to be more volatile and carry heightened regulatory and legal risk because laws and enforcement vary by jurisdiction, so investors often focus on licensing, cash flow, and a clear path to profitability. These companies had the highest dollar trading volume of any Cannabis stocks within the last several days.
Akanda (AKAN)
Read Our Latest Research Report on AKAN
Tilray Brands (TLRY)
Read Our Latest Research Report on TLRY
Canopy Growth (CGC)
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments.
Read Our Latest Research Report on CGC
SNDL (SNDL)
SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores.
Read Our Latest Research Report on SNDL
Quantum Biopharma (QNTM)
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.
Read Our Latest Research Report on QNTM
See Also
- MarketBeat’s Top Five Stocks to Own in May 2026
- MaxLinear’s Explosive 200% Rally Looks Impressive—But Can It Last?
- 5 Reasons Rambus Stock Price Collapse Is One Hot Entry Point
- Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge
- Bed Bath & Back to Life? An Aggressive Turnaround Takes Shape
- Apple’s Earnings Make $300 Look Like a Matter of When, Not If
